Nano-sized polymers and liposomes designed to deliver combination therapy for cancer

Current Opinion in Biotechnology

Volumn 24, Issue 4, 2013, Pages 682-689

  Eldar Boock, Anat ^a   Polyak, Dina ^a   Scomparin, Anna ^a   Satchi Fainaro, Ronit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BIOACTIVE AGENTS; COMBINATION THERAPY; DRUG DELIVERY SYSTEM; LATEST DEVELOPMENT; MECHANISMS OF RESISTANCES; STANDARD OF CARES; SYSTEMIC TOXICITIES; THERAPEUTIC AGENTS;

COORDINATION REACTIONS; DISEASES; DRUG DELIVERY; DRUG INTERACTIONS; LIPOSOMES; OLIGONUCLEOTIDES;

POLYMERS;

ANTINEOPLASTIC AGENT; BETA1 INTEGRIN; CILENGITIDE; CISPLATIN; CURCUMIN; DENDRIMER; DOXORUBICIN; FLUOROURACIL; FUMAGILLOL CHLOROACETYLCARBAMATE; KINESIN SPINDLE PROTEIN; LIPOSOME; LOW MOLECULAR WEIGHT HEPARIN; MACROGOL; MICRORNA; MYC PROTEIN; NANOCARRIER; PACLITAXEL; PALMITOLEIC ACID; PARTHENOLIDE; POLY(BUTYL CYANOACRYLATE); POLYGLUTAMIC ACID; POLYMER; PROTEIN BCL 2; REGULATOR PROTEIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; SURVIVIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VITRONECTIN RECEPTOR;

BIODEGRADABILITY; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; GENE SILENCING; HUMAN; HYDROPHILICITY; MALIGNANT NEOPLASTIC DISEASE; MICELLE; MOLECULAR WEIGHT; NANOENCAPSULATION; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; GENE SILENCING; HUMANS; LIPOSOMES; NANOPARTICLES; NEOPLASMS;

EID: 84880930108     PISSN: 09581669     EISSN: 18790429     Source Type: Journal    
DOI: 10.1016/j.copbio.2013.04.014     Document Type: Review

References (57)

1. Greco F., Vicent M.J. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv Drug Deliv Rev 2009, 61:1203-1213.
2. Haag R., Kratz F. Polymer therapeutics: concepts and applications. Angew Chem Int Ed Engl 2006, 45:1198-1215.
3. Eichhorn M.E., Strieth S., Dellian M. Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives. Drug Resist Updat 2004, 7:125-138.
4. Tiram G., et al. Interfering cancer with polymeric siRNA nanocarriers. J Biomed Nanotechnol 2013, in press.
5. Khandare J., et al. Multifunctional dendritic polymers in nanomedicine: opportunities and challenges. Chem Soc Rev 2012, 41:2824-2848.
6. Duncan R. Polymer therapeutics as nanomedicines: new perspectives. Curr Opin Biotechnol 2011, 22:492-501.
7. Duncan R., Vicent M.J. Polymer therapeutics-prospects for 21st century: the end of the beginning. Adv Drug Deliv Rev 2013, 65:60-70.
8. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46:6387-6392.
9. Fang J., Nakamura H., Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011, 63:136-151.
10. Markovsky E., et al. Administration, distribution, metabolism and elimination of polymer therapeutics. J Control Release 2012, 161:446-460.
11. Wang H., et al. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials 2011, 32:8281-8290.
12. Segal E., et al. Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances. Biomaterials 2011, 32:4450-4463.
13. Jin C., et al. Combination chemotherapy of doxorubicin and paclitaxel for hepatocellular carcinoma in vitro and in vivo. J Cancer Res Clin Oncol 2010, 136:267-274.
14. Rosati M.S., et al. Weekly combination of non-pegylated liposomal doxorubicin and taxane in first-line breast cancer: wALT trial (phase I-II). Ann Oncol 2011, 22:315-320.
15. Lage H. ABC-transporters: implications on drug resistance from microorganisms to human cancers. Int J Antimicrob Agents 2003, 22:188-199.
16. Duan J., et al. Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles. Int J Pharm 2012, 426:193-201.
17. Sadzuka Y., et al. Beneficial effects of curcumin on antitumor activity and adverse reactions of doxorubicin. Int J Pharm 2012, 432:42-49.
18. Riedel R.F., et al. A genomic approach to identify molecular pathways associated with chemotherapy resistance. Mol Cancer Ther 2008, 7:3141-3149.
19. Zhang D., et al. Nuclear factor-kappaB inhibition by parthenolide potentiates the efficacy of Taxol in non-small cell lung cancer in vitro and in vivo. Mol Cancer Res 2009, 7:1139-1149.
20. Shin H.C., et al. Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs. J Control Release 2009, 140:294-300.
21. Gill K.K., Kaddoumi A., Nazzal S. Mixed micelles of PEG(2000)-DSPE and vitamin-E TPGS for concurrent delivery of paclitaxel and parthenolide: enhanced chemosenstization and antitumor efficacy against non-small cell lung cancer (NSCLC) cell lines. Eur J Pharm Sci 2012, 46:64-71.
22. Hlatky L., Hahnfeldt P., Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 2002, 94:883-893.
23. Lee E., et al. Polyproline-type helical-structured low-molecular weight heparin (LMWH)-taurocholate conjugate as a new angiogenesis inhibitor. Int J Cancer 2009, 124:2755-2765.
24. Ma X., Ezzeldin H.H., Diasio R.B. Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs 2009, 69:1911-1934.
25. Kim J.Y., et al. Tumor vasculature targeting following co-delivery of heparin-taurocholate conjugate and suberoylanilide hydroxamic acid using cationic nanolipoplex. Biomaterials 2012, 33:4424-4430.
26. Satchi-Fainaro R., Mann-Steinberg H. TNP-470: the resurrection of the first synthetic angiogenesis inhibitor. Angiogenesis: An Integrative Approach from Science to Medicine 2008, 387-406. Springer-Verlag, Heidelberg, Germany. J. Figg, Folkman (Eds.).
27. Lipton A. Emerging role of bisphosphonates in the clinic-antitumor activity and prevention of metastasis to bone. Cancer Treat Rev 2008, 34:S25-S30.
28. Miller K., et al. Antiangiogenic antitumor activity of HPMA copolymer-paclitaxel-alendronate conjugate on breast cancer bone metastasis mouse model. Mol Pharm 2011, 8:1052-1062.
29. Miller K., et al. Poly(ethylene glycol)-paclitaxel-alendronate self-assembled micelles for the targeted treatment of breast cancer bone metastases. Biomaterials 2013.
30. Dai W., et al. Spatiotemporally controlled co-delivery of anti-vasculature agent and cytotoxic drug by octreotide-modified stealth liposomes. Pharm Res 2012, 29:2902-2911.
31. Liu P., et al. cRGD conjugated mPEG-PLGA-PLL nanoparticles for SGC-7901 gastric cancer cells-targeted Delivery of fluorouracil. J Nanosci Nanotechnol 2012, 12:4467-4471.
32. Graf N., et al. alpha(V)beta(3) integrin-targeted PLGA-PEG nanoparticles for enhanced anti-tumor efficacy of a Pt(IV) prodrug. ACS Nano 2012, 6:4530-4539.
33. Polyak D., et al. Development of PEGylated doxorubicin-E-[c(RGDfK)2] conjugate for integrin-targeted cancer therapy. Polym Adv Technol 2011, 103-113.
34. Eldar-Boock A., et al. Integrin-assisted drug delivery of nano-scaled polymer therapeutics bearing paclitaxel. Biomaterials 2011, 32:3862-3874.
35. Zhu C., et al. Co-delivery of siRNA and paclitaxel into cancer cells by biodegradable cationic micelles based on PDMAEMA-PCL-PDMAEMA triblock copolymers. Biomaterials 2010, 31:2408-2416.
36. Huang H.Y., et al. Co-delivery of anti-vascular endothelial growth factor siRNA and doxorubicin by multifunctional polymeric micelle for tumor growth suppression. J Biomed Mater Res A 2011, 97:330-338.
37. Chang R.S., et al. Cationic drug-derived nanoparticles for multifunctional delivery of anticancer siRNA. Biomaterials 2011, 32:9785-9795.
38. Cao N., et al. The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells. Biomaterials 2011, 32:2222-2232.
39. Chen Y., et al. Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. J Biol Chem 2010, 285:22639-22650.
40. Yin Q., et al. Overcoming multidrug resistance by co-delivery of Mdr-1 and survivin-targeting RNA with reduction-responsible cationic poly(beta-amino esters). Biomaterials 2012, 33:6495-6506.
41. Tabernero J., et al. First-in-man trial of an rna interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov 2013, 3(4):406-417.
42. Cox D., et al. The pharmacology of the integrins. Med Res Rev 1994, 14:195-228.
43. Avraamides C.J., Garmy-Susini B., Varner J.A. Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer 2008, 8:604-617.
44. Danhier F., Breton A.L., Preat V. RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Mol Pharm 2012, 9(11):2961-2973.
45. Matsunaga T., et al. Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia. Leukemia 2008, 22:353-360.
46. Sun L.C., et al. A conjugate of camptothecin and a somatostatin analog against prostate cancer cell invasion via a possible signaling pathway involving PI3K/Akt, alphaVbeta3/alphaVbeta5 and MMP-2/-9. Cancer Lett 2007, 246:157-166.
47. Meister G., Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature 2004, 431:343-349.
48. Leng Q., et al. Advances in Systemic siRNA Delivery. Drugs Future 2009, 34:721.
49. Duhem C., Ries F., Dicato M. What does multidrug resistance (MDR) expression mean in the clinic?. Oncologist 1996, 1:151-158.
50. Patil Y.B., et al. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials 2010, 31:358-365.
51. Kubowicz P., Zelaszczyk D., Pekala E. RNAi in clinical studies. Curr Med Chem 2013, 20(14):1801-1816.
52. Logman J.F., et al. Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK. Ann Oncol 2010, 21:1529-1536.
53. Ringsdorf H. Structure and properties of pharmacologically active polymers. J Polym Sci Polym Symp 1975, 135-153.
54. Jatzkewits H. Peptamin (glycyl-l-leucyl-mescaline) bound to blood plasma expander (polyvinylpyrrolidone) as a new depot form of a biologically active primary amine (mescaline). Z. NatuNaturforsch 1955, 27-31.
55. Givental N.I., et al. Experimental studies on penicillin polymer derivatives. Antibiotiki 1965, 10:701-706.
56. Baabur-Cohen H., Omer O., Satchi-Fainaro R. Recent progress in polymer therapeutics as nanomedicines. Handbook of Harnessing biomaterials in Nanomedicine: Preparation, Toxicity and Applications 2011, 77-122. Pan Stanford Publishing Pte. Ltd., Hackensack, NJ, USA. D. Peer (Ed.).
57. Branco M.C., Schneider J.P. Self-assembling materials for therapeutic delivery. Acta Biomater 2009, 5:817-831.